Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
patiently waiting sure was a lot easier to do than engaging in the ton of noise that occurred between now and my last post. Congrats to all longs who held. In since .035
Multistem trial for moderate to severe UC success
Multistem trial for moderate to severe UC success - Ulcerative Colitis - HealingWell.com Forum
I'm confident I received the Multistem because I have slowly improved every day and am pretty sure I'm in complete remission now (I go back in two weeks for another look see). At any rate, I encourage any of you who are suffering and not being helped by the drugs we have available to us to check into this trial. Let me know if there are others of you having any results with this trial please.
I got into the trial and have not ever tried biological or immunosuppressive drugs. I failed mesalamine sulfasalazine and uceris. Yes I am still doing great. I had my 8 week flex sig last Friday and while there are still some ulcers they are much improved and symptom wise I am in Complete remission. My iron levels have even finally made it back to the normal range after being low for months. I have not experienced any side effects and while there is always risk of side effects in the future I am so thankful to try an option that might be safer than those other nasty drugs. Furthermore to the above post about the high dangers of stem cells transplants read up on multistem....they are different than a traditional stem cell transplant. I'm more than happy to answer any other questions you guys have as I feel this may truly be a viable option for us uc people in the future.
School has started and whatever amount I have put into AMBS I consider gone. Too much chatter about short-term immaterial things. Time to follow the stock solely through PR's sent by email from the company. See you all again when some actual substansive news is released, good or bad.
That's quite the conjecture..
Guessing there is no webcast for the presentation today?
It would be nice to a bit closer and visit the Almanor Ave. office and meet Gerald in person. Hopefully once at Stanford Business School, doing so will be of great convenience and the company headquarters will be far more advanced.
As far as market cap goes, AMBS looks to be the smallest company presenting at the Aegis Healthcare Conference. Much more solid companies here relative to the prior conference Gerald attended, like Acorda, Amarin, and several others.
Monrovia here. AMBS So-Cal meetup after news??
Exactly.
Welcome to speculation. All we can do is our own DD, place our own bets, and wait for things to unfold as they will. Nothing more. People here seem to really have a difficult time embracing this logic.
Strange to have that email sent out again, I thought the same thing when I saw the it in my inbox lol
Another $1200 is more than welcome
Don't count out anytime in the next 1.5 hours either. He's done it before and it worked
Just goes to show how powerful an actual move based on substansive news will be. Easiest $1200 i've ever made.
what a nice trade it was to pick up 100k at 0.063. these games never end
"We are currently establishing analytical performance, expect data towards the end of this quarter that will be released."
"We have some pilot clinical performance studies to characterize and confirm the literature which is in our hand and will be released in the 4th quarter"
"Will be initiating a pivotal CLIA registering study in the first half of 2014 with commercialization expected in the first half of next year"
"At that point, we should be, on our diagnostic side, commercial-stage, which is obviously a major value inflection. And the science of LymPro has been getting better and better over time"
3:00-3:55 in presentation
Keep trolling
"We are currently establishing analytical performance, expect data towards the end of this quarter that will be released."
"We have some pilot clinical performance studies to characterize and confirm the literature which is in our hand and will be released in the 4th quarter"
"Will be initiating a pivotal CLIA registering study in the first half of 2014 with commercialization expected in the first half of next year"
"At that point, we should be, on our diagnostic side, commercial-stage, which is obviously a major value inflection. And the science of LymPro has been getting better and better over time"
3:00-3:55 in presentation
Keep trolling
Chase those pennies
Bingo. People here are so worried about every little tick, they dont realize the most return theyre going to get on this is by sitting on it until further news develops
I can honestly say that after all of the presentations by Gerald that I've listened to and watched over time, I feel most confortable as a shareholder after this one. There's just so much to look forward to in the coming days, weeks, months, and years. Very exciting time to be a part of Amarantus.
"We have data for a second orphan indication in hand that we will release shortly"
"The science of LymPro has been getting better and better over time"
Slides for presentation are up as of a minute ago
And here we go...
A few trendlines and indicators will be shifted around to show how the stock was actually poised to break out. Any news was therefore immaterial. lol.
My "indicators" and "sources" tell me the stock price will go up if there is any positive news, and down if there is negative news or none whatsoever. I have a strangely powerful feeling that my "chart signals" are correct.
There is so much information in this study. Have a look for yourselves.
Armet/Manf and Creld2 are components of a specialized ER stress response provoked by inappropriate formation of disulphide bonds: implications for genetic skeletal diseases
Armet, also known as MANF (Mesencephalic Astrocyte derived Neurotrophic Factor), was identified as a gene up-regulated by various forms of ER stress in different cell lines and by cerebral ischaemia in rat (26–28). The expression of Armet was not only similar to that of the molecular chaperone BiP/GRP78, but the upregulation of Armet was also shown to be mediated by an ERSE-II element, which is frequently found in the promoters of ER chaperone genes (27). Furthermore, the over-expression of Armet in HeLa cells inhibited cell proliferation and ER stress-induced cell death (26). Interestingly, two important disease mechanisms in the Matn3 V194D mouse include a reduction in chondrocyte proliferation and dysregulated apoptosis (10,12), suggesting an influence of Armet in the initiation and/or progression of MED.
We demonstrate that Armet and Creld2 are genotype-specific ER stress response proteins with substrate specificities, and that aggregation of mutant matrilin-3 is a key disease trigger in MED that could be exploited as a potential therapeutic target.
http://hmg.oxfordjournals.org/content/early/2013/08/22/hmg.ddt383.long
September 2013, Volume 18, Issue 3, pp 398-415
Transcriptional regulation of mouse mesencephalic astrocyte-derived neurotrophic factor in Neuro2a cells
Abstract
Mesencephalic astrocyte-derived neurotrophic factor (MANF) is a novel type of trophic factor. Recent studies indicate that the MANF gene is induced in response to endoplasmic reticulum (ER) stress through ER stress response element II (ERSE-II) in its 5'-flanking region. In this study, we evaluated the roles of six ER stress response transcription factors in the regulation of the promoter activities of the mouse MANF gene via ERSE-II using various types of mutant MANF luciferase reporter constructs. Treatment with thapsigargin (Tg) induced MANF mRNA generation in parallel with the elevation of ATF6a, sXBP and Luman mRNA levels in Neuro2a cells. Of the six transcription factors, ATF6ß most strongly increased the MANF promoter activity via ERSE-II, while the effects of ATF6ß and sXBP1 were moderate. However, overexpression of Luman or OASIS did not enhance ERSE-II-dependent MANF promoter activity in Neuro2a cells. To evaluate the relationships between transcription factors in the regulation of ERSE-II-dependent MANF promoter activity, we transfected two effective transcription factor constructs chosen from ATF6a, ATF6ß, uXBP1 and sXBP1 into Neuro2a cells with the MANF reporter construct. The MANF promoter activity induced by co-transfection of ATF6a with ATF6ß was significantly lower than that induced by ATF6a alone, while other combinations did not show any effect on the ERSE-II-dependent MANF promoter activity in Neuro2a cells. Our study is the first to show the efficiency of ER stress-related transcription factors for ERSE-II in activating the transcription of the mouse MANF gene in Neuro2a cells.
http://link.springer.com/article/10.2478%2Fs11658-013-0096-x
I've had "the idea" for quite some time now, hence being up 500%.
My point is that what I consider an investment is an asset that pays me for being a shareholder; real estate or companies that are built on solid foundations and consistently generate higher profits and pay investors regularly OR buy back shares.
There's nothing wrong with being an AMBS shareholder; in fact, I'm thrilled about it, but AMBS has not reached the "investment" level yet, which is the exciting part of this development-stage biotech company with, according to my speculation, a very bright future.
But the bottom line is every "long" here is buying shares of this company expecting someone else to be willing to pay more for the shares at a later time. I happen to believe our judgement will be accurate.
Valuation is contingent upon release of positive data/validation in the coming days/weeks. Even Jason is waiting for news from Gerald before writing up his next article and calculating a new valuation. Regardless of strong, encouraging support received by the company (e.g Rubinfeld and the rest of the board of advisors) being a shareholder of this company is unfortunately not an investment at this stage of the game; it is a gamble. No questions asked. I've placed my bets, however, and it's for the company to succeed. There's really not much more one can say. Time will reveal all.
Saw the conference news last week. Guess it was only a matter of time before it got PR'ed.
Considering there is usually a PR put out alongside numerous twitter reminders of whenever AMBS has an upcoming appearance, it appears that there has purposely been an absence of a PR about the large conference next Tuesday because data being released the day prior would provide all the "press" the company would want for its presentation. Just IMO.
Worried about a .0002 difference; gotta be trolling
Bulls make money, bears make money, pigs get slaughtered.
Still wondering why the Amarantus presentation at Rodman and Renshaw Annual Global Investment Conference next Tuesday was never announced through a company PR like all the other companies had done.
Can anyone find the www.wsw.com link for their webcast, if available?
Some more speculation for the fun of it: could it be that they will announce data monday morning and go over a commercialization plan at the conference the next day with all eyes on them?
Same here. Got a GTC sell for $25. Let it take 5, 10, or 20 years - makes no difference.
Yes, but there was never a company PR put out. This one looks to be pretty big. They're second to last public company to present in the entire conference on tuesday afternoon.
Was anyone aware of this?
I don't recall seeing it anywhere prior to this morning.
Rodman & Renshaw ?@Rodman_2013 45m
Take a look at Amarantus BioScience who is schedule to present at #Rodman2013. http://bit.ly/Ubk5xM $AMBS @AmarantusBio
Since this is the only speculative stock I own in my portfolio, here's some "speculation" over recent developments.
It would not be surprising if Gerald were to releas data tomorrow morning or early next week.
In my opinion:
-Gerald has positive data in hand
-Completes financing to improve balance sheet to improve the appearance of company solvency through its balance sheet for prospective partners
-Appoints Dr. Bier for, obviously, commercialization
-Attends conference for the sole purpose of presenting the commercialization strategy for LymPro to prospective partners, giving a gesture of "here's exactly what you can expect in return for your investment"
Shares of AMBS have been purchased with nothing but profits taken from other investments, and if none of the company's objectives were to materialize over the years, which I doubt given my position, oh well; that's where profits from actual "investing" come in and outweigh the circumstances. On the other hand, I have no intentions of selling; it would be great to see this company grow over years to its full potential and be alone for the ride the entire way.
AMBS
p.s gotta work on my "quoting game" and get on BH's level
His "source" is probably himself, but, regardless, his comments have gone unaddressed and intrigued me.
Couple questions someone with the username "coldcoffee123" asked on SA in regards to an article written by Jason about Lympro. Any opinions/answers to these questions? Just curious:
According to my sources, BD LymPro results have come out of negative. They will not be receiving any funding from BD for CLIA. That is the reason why AMBS had to raise $3M immediately. Expect the stock to trade around $0.035 range later this week.
Any idea why nobody is ready to fund AMBS's research? With Rubinfeld on board, can he not drop a word or two to Amgen? Amgen can spend 11B for Onyx, but nothing for AMBS? They can buy AMBS Diagnostics+Therapeutics for dirt cheap and it could turn out to be great investment. Surely somebody must be eyeing AMBS, don''t you think?? Hard to believe Big Pharma that are always scouting for golden opportunities for acquisition are turning a blind eye to AMBS. Could it be that AMBS is a scam?
Some of the recent peer-reviewed publications are coming from independent groups working on MANF. How does their success (for whatever indications they are researching on) help AMBS? For example, lets suppose one of these research groups manages to get orphan designation for Fairbanks. How does that help AMBS, other than the fact that it involves MANF? How does MANF patents benefit AMBS for research that is not directly being done by AMBS? Will these groups be required to pay anything to AMBS? Can they refuse to do so? Sorry, I have no idea how patents work !